Transepithelial Transport and Enzymatic Detoxification of Gluten in Gluten-Sensitive Rhesus Macaques

Michael T. Bethune, Erin Ribka, Chaitan Khosla et al. · 2008

Read Transepithelial Transport and Enzymatic Detoxification of Gluten in Gluten-Sensitive Rhesus Macaques by Michael T. Bethune, Erin Ribka, Chaitan Khosla et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001857.txt.

Introduction

Michael T. Bethune, Erin Ribka, Chaitan Khosla, and their co-authors studied gluten handling in gluten-sensitive macaques in a 2008 PLOS ONE research article. In previous work the group characterized gluten sensitivity in juvenile rhesus macaques similar in many respects to human celiac disease. The animal model may therefore be useful for studying both how gluten crosses the gut lining and how it can be detoxified.

The team examined transepithelial transport and enzymatic detoxification of gluten in these macaques. The full text gives the transport measurements and the enzyme treatments. Enzyme pills that digest gluten in the stomach are a leading celiac therapy idea. This primate model tests them in a gut much like ours.

Catalog record

CREATORMichael T. Bethune, Erin Ribka, Chaitan Khosla et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001857

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Transepithelial Transport and Enzymatic Detoxification of Gluten in Gluten-Sensitive Rhesus Macaques Authors: Michael T. Bethune, Erin Ribka, Chaitan Khosla, Karol Sestak Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001857 ABSTRACT In a previous report, we characterized a condition of gluten sensitivity in juvenile rhesus macaques that is similar in many respects to the human condition of gluten sensitivity, celiac disease. This animal model of gluten sensitivity may therefore be useful toward studying both the pathogenesis and the treatment of celiac disease. Here, we perform two pilot experiments to demonstrate the potential utility of this model for studying intestinal permeability toward an immunotoxic gluten peptide and pharmacological detoxification of gluten in vivo by an oral enzyme drug candidate. Intestinal permeability was investigated in age-matched gluten-sensitive and control macaques by using mass spectrometry to detect and quantify an orally dosed, isotope labeled 33-mer gluten peptide delivered across the intestinal epithelium to the plasma. The protective effect of a therapeutically promising oral protease, EP-B2, was evaluated in a gluten-sensitive macaque by administering a daily gluten challenge with or without EP-B2 supplementation. ELISA-based antibody assays and blinded clinical evaluations of this macaque and of an age-matched control were conducted to assess responses to gluten. Labeled 33-mer peptide was detected in the plasma of a gluten-sensitive macaque, both in remission and during active disease, but not in the plasma of healthy controls. Administration of EP-B2, but not vehicle, prevented clinical relapse in response to a dietary gluten challenge. Unexpectedly, a marked increase in anti-gliadin (IgG and IgA) and anti-transglutaminase (IgG) antibodies was observed during the EP-B2 treatment phase. Gluten-sensitive rhesus macaques may be an attractive resource for investigating important aspects of celiac disease, including enhanced intestinal permeability and pharmacology of oral enzyme drug candidates. Orally dosed EP-B2 exerts a protective effect against ingested gluten. Limited data suggest that enhanced permeability of short gluten peptides generated by gastrically active glutenases may trigger an elevated antibody response, but that these antibodies are not necessarily causative of clinical illness. INTRODUCTION Celiac disease is an inheritable enteropathy caused by dietary gluten from common food grains such as wheat, rye, and barley [1] . Unlike most other dietary proteins, gluten is incompletely digested by gastrointestinal proteases, yielding proteolytically resistant peptides that trigger a deleterious immune response in genetically susceptible individuals [2] . To widely varying degrees in celiac patients, this immune response produces intestinal effects, such as mucosal damage, malabsorption, and clinical diarrhea, as well as systemic humoral effects, such as the production of anti-gliadin antibodies (AGA) and anti-transglutaminase 2 (TG2) autoantibodies [3] , [4] . The only existing therapy for celiac disease is a gluten-free diet, which is effective in most celiac patients when strictly followed [5] . However, the maintenance of this diet is extremely difficult due to the ubiquity of gluten in most human diets, and relapse due to accidental ingestion of gluten contained in inadequately labeled or gluten-contaminated foods is an abiding concern and a frequent occurrence for treated celiac patients [6] – [9] . Several properties of immunogenic gluten peptides have been identified as being critical toward their pathogenic role in celiac disease [10] . These include proteolytic resistance due to high proline and glutamine content [2] , [11] , presence of preferred glutamine residues for TG2-mediated glutamine deamidation [12] , [13] , and high affinity of these deamidated sequences for human leukocyte antigen (HLA)-DQ2 [14] , [15] , a class II major histocompatibility complex (MHC) molecule associated with over 90% of diagnosed celiac patients [16] , [17] . Additionally, longer peptides containing multiple epitopes appear to be more immunotoxic than their constituent epitopes [2] , [18] . One peptide in particular, a 33-mer derived from in vitro gastrointestinal proteolysis of α2-gliadin, possesses all of these characteristics and activates proliferation in all celiac patient-derived T cell lines tested so far [2] , [19] . Moreover, this peptide is detected as a stable digestive product of ingested gluten in both rats [20] and cynomolgus monkeys (MTB, unpublished results), suggesting it is likely produced from dietary gluten in the human gut as well. It is therefore presumed that the 33-mer is important in the induction and propagation of the adverse response to gluten in celiac disease patients. To enact such a role in vivo , however, this relatively large (∼4 kDa) peptide must be transported intact across the mucosal epithelium to the underlying lymphoid tissue where it can be presented by DQ2 on antigen presenting cells to gluten-specific CD4+ T cells. Despite strong evidence implicating gluten peptides in celiac disease pathogenesis, the detection of a chemically-defined gluten peptide in extra-intestinal body fluids following oral dosing has yet to be reported, and the extent to which disease state alters permeability toward such a peptide is unclear. It is well established that active enteropathy is associated with structurally altered tight junctions [21] and increased permeability toward small (<1 kDa) non-permeating molecules [22] – [26] , and that these defects are not completely resolved by a gluten-free diet [21] , [23] – [25] . However, it is unclear whether these findings will translate to increased permeability toward gluten peptides of sufficient size to elicit an immune response. Further, studies of intestinal permeability with respect to disease state in celiac patients are hampered by the practical difficulty of ensuring strict dietary exclusion of gluten [6] – [9] . An animal model of gluten sensitivity could enable the observation and study of transepithelial gluten peptide delivery in an in vivo system in which dietary gluten content can be absolutely controlled. Furthermore, such an animal model could facilitate preclinical testing of pharmacological therapies aimed at protecting celiac patients from the constant risk of dietary gluten exposure. In a previous report, we characterized a condition of gluten sensitivity in juvenile rhesus macaques ( Macaca mulatta ) that is similar in many respects to celiac disease [27] . Affected animals exhibited intestinal lesions, malabsorptive steatorrhea, clinical diarrhea, and elevated anti-gliadin (though not anti-TG2) antibodies in response to a gluten-containing diet. Administration of a gluten-free diet to one such affected animal, FH09, caused complete remission, whereas reintroduction of dietary gluten caused clinical, histological, and serological relapse. Similar dietary changes had no effect on an age-matched control, FR26. In this report, we conduct two pilot studies using the gluten-sensitive macaque model. The first study investigates the fundamental question of whether the immunotoxic 33-mer peptide is delivered intact across the intestinal epithelium in gluten-sensitive FH09, during both remission and relapse, as well as in healthy control FR26. We use mass spectrometry to detect for the first time the transepithelial delivery of a chemically-defined, immunotoxic gluten peptide in a gluten-sensitive organism. The second study investigates the practical question of whether oral protease therapy can protect a second gluten-sensitive animal, FH45, from gluten challenge-induced relapse. We present clinical and serological data for FH45, and for control FI96, showing that EP-B2, a gluten-specific endoprotease with potential as a therapeutic for celiac disease [20] , [28] – [30] , prevents clinical relapse in FH45 in response to a gluten challenge. However, this treatment gives rise to an unexpected elevation in anti-gliadin and anti-TG2 antibodies, the implications of which are discussed. METHODS Gluten-sensitive juvenile macaques, FH09 and FH45, were selected for dietary treatment and pilot

Read the complete text